SCHEMBL2115295

SCHEMBL2115295

O=C(N[C@H]1c2cc(N3CCNCC3)ccc2OC[C@@H]1O)c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.55
DGAT2 Q96PD7 1/20 0.46
MAOB P27338 1/20 0.43
TP53 P04637 2/20 0.41
FLT3 P36888 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KDR P35968 1/20 0.38
NPC1 O15118 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HDAC3 O15379 3/20 0.37
HTR1A P08908 1/20 0.37
HTR7 P34969 1/20 0.37
BMPR1B O00238 1/20 0.37
BMPR1A P36894 1/20 0.37
TGFBR1 P36897 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2732555 1.00 CTSS (0.55) CTSSDGAT2MAOBTP53FLT3
Hydrochloric Acid SCHEMBL2113519 0.99 CTSS (0.54) CTSSDGAT2MAOBTP53FLT3
SCHEMBL2610211 0.90 CTSS (0.49) CTSSDGAT2MAOBTP53FLT3
Hydrochloric Acid SCHEMBL2114956 0.89 CTSS (0.49) CTSSDGAT2MAOBTP53FLT3
SCHEMBL2732060 0.86 CTSS (0.72) CTSSDGAT2TP53ALDH1A1MAPT
SCHEMBL2115205 0.86 CTSS (0.72) CTSSDGAT2TP53ALDH1A1MAPT
SCHEMBL2726320 0.82 CHRM1 (0.50) CTSSMAOB
SCHEMBL2610209 0.81 CTSS (0.52) CTSSMAOBTP53KDRNPC1
Hydrochloric Acid SCHEMBL2115298 0.80 CTSS (0.51) CTSSMAOBTP53KDRNPC1
SCHEMBL2114479 0.80 DGAT2 (0.47) CTSSDGAT2MAOBTP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630141-A1 CATHEPSIN S INHIBITOR COMPOUNDS Eli Lilly and Company (US) 2013-08-28 EP disclosed
US-8227468-B2 Cathepsin S inhibitor compounds ELI LILLY AND COMPANY (US) 2012-07-24 US disclosed
US-8227468-B2 Cathepsin S inhibitor compounds ELI LILLY AND COMPANY (US) 2012-07-24 US disclosed
US-8227468-B2 Cathepsin S inhibitor compounds ELI LILLY AND COMPANY (US) 2012-07-24 US disclosed
WO-2012054315-A1 CATHEPSIN S INHIBITOR COMPOUNDS ELI LILLY AND COMPANY (US) 2012-04-26 WO disclosed
WO-2012054315-A1 CATHEPSIN S INHIBITOR COMPOUNDS ELI LILLY AND COMPANY (US) 2012-04-26 WO disclosed
US-20120095020-A1 Cathepsin S Inhibitor Compounds ELI LILLY AND COMPANY (US) 2012-04-19 US disclosed
US-20120095020-A1 Cathepsin S Inhibitor Compounds ELI LILLY AND COMPANY (US) 2012-04-19 US disclosed
US-20120095020-A1 Cathepsin S Inhibitor Compounds ELI LILLY AND COMPANY (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095020-A1 Cathepsin S Inhibitor Compounds CTSS, CTSZ, CTSV CTSS 1/4885DGAT2 3382/4885MAOB 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.